MaxCyte (MXCT) Stock Forecast, Price Target & Predictions
MXCT Stock Forecast
MaxCyte stock forecast is as follows: an average price target of $8.00 (represents a 98.51% upside from MXCT’s last price of $4.03) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MXCT Price Target
The average price target for MaxCyte (MXCT) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 98.51% upside from MXCT's last price of $4.03.
MXCT Analyst Ratings
According to 2 Wall Street analysts, MaxCyte's rating consensus is 'Buy'. The analyst rating breakdown for MXCT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MaxCyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 13, 2024 | Mark Massaro | BTIG | $8.00 | $4.16 | 92.31% | 98.51% |
| Aug 14, 2022 | Mark Massaro | BTIG | $11.00 | $5.87 | 87.39% | 172.95% |
The latest MaxCyte stock forecast, released on Mar 13, 2024 by Mark Massaro from BTIG, set a price target of $8.00, which represents a 92.31% increase from the stock price at the time of the forecast ($4.16), and a 98.51% increase from MXCT last price ($4.03).
MaxCyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $4.03 | $4.03 | $4.03 |
| Upside/Downside | -100.00% | -100.00% | 98.51% |
In the current month, the average price target of MaxCyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MaxCyte's last price of $4.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 03, 2024 | Deutsche Bank | - | Hold | Initialise |
| Mar 13, 2024 | BTIG | Buy | Buy | Hold |
| Aug 14, 2022 | BTIG | Buy | Buy | Hold |
MaxCyte's last stock rating was published by Deutsche Bank on May 03, 2024. The company Initialise its MXCT rating from "null" to "Hold".
MaxCyte Financial Forecast
MaxCyte Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $15.66M | $8.00B | $9.04B | $8.58M | $12.42M | $10.64M | $9.61M | $11.59M | $10.15M | $10.14M | $7.11M | $5.15M | - |
| Avg Forecast | $12.64M | $11.30M | $10.92M | $9.95M | $7.92M | $7.46M | $7.97M | $7.51M | $13.44M | $8.87M | $10.66M | $8.27M | $12.40M | $10.43M | $9.23M | $8.46M | $9.56M | $7.28M | $5.79M | $13.39M | $8.40M |
| High Forecast | $13.38M | $11.95M | $11.56M | $10.53M | $8.38M | $7.76M | $8.43M | $7.94M | $15.45M | $9.39M | $11.28M | $8.76M | $13.12M | $11.04M | $9.68M | $8.88M | $10.03M | $7.64M | $6.07M | $14.05M | $8.81M |
| Low Forecast | $11.66M | $10.42M | $10.07M | $9.18M | $7.31M | $7.16M | $7.35M | $6.92M | $11.44M | $8.18M | $9.83M | $7.63M | $11.44M | $9.62M | $8.69M | $7.97M | $9.00M | $6.85M | $5.45M | $12.60M | $7.91M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.17% | 902.42% | 848.41% | 1.04% | 1.00% | 1.02% | 1.04% | 1.37% | 1.06% | 1.39% | 1.23% | 0.38% | - |
MaxCyte's average Quarter revenue forecast for Mar 24 based on 2 analysts is $7.51M, with a low forecast of $6.92M, and a high forecast of $7.94M. MXCT's average Quarter revenue forecast represents a -52.09% decrease compared to the company's last Quarter revenue of $15.66M (Dec 23).
MaxCyte EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $15.66M | $-12.13B | $-11.12B | $-12.22M | $-3.88M | $-5.61M | $-7.71M | $-3.58M | $-3.45M | $-2.03M | $-4.41M | $-2.84M | - |
| Avg Forecast | $-7.27M | $-6.50M | $-6.28M | $-5.72M | $-4.56M | $-4.29M | $-4.58M | $-4.32M | $-7.73M | $-5.10M | $-6.13M | $-4.76M | $-7.13M | $-6.00M | $-5.31M | $-4.87M | $-5.50M | $-2.55M | $-3.33M | $-7.70M | $-4.83M |
| High Forecast | $-6.71M | $-5.99M | $-5.79M | $-5.28M | $-4.20M | $-4.12M | $-4.23M | $-3.98M | $-6.58M | $-4.71M | $-5.66M | $-4.39M | $-6.58M | $-5.53M | $-5.00M | $-4.58M | $-5.18M | $-2.04M | $-3.13M | $-7.25M | $-4.55M |
| Low Forecast | $-7.69M | $-6.87M | $-6.65M | $-6.05M | $-4.82M | $-4.46M | $-4.85M | $-4.57M | $-8.88M | $-5.40M | $-6.49M | $-5.04M | $-7.55M | $-6.35M | $-5.57M | $-5.10M | $-5.77M | $-3.06M | $-3.49M | $-8.08M | $-5.07M |
| Surprise % | - | - | - | - | - | - | - | - | -2.03% | 2377.37% | 1814.01% | 2.57% | 0.54% | 0.93% | 1.45% | 0.74% | 0.63% | 0.79% | 1.33% | 0.37% | - |
2 analysts predict MXCT's average Quarter EBITDA for Mar 24 to be $-4.32M, with a high of $-3.98M and a low of $-4.57M. This is -127.55% lower than MaxCyte's previous annual EBITDA (Dec 23) of $15.66M.
MaxCyte Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-11.25B | $-10.51B | $-8.59M | $-2.87M | $-5.16M | $-7.78M | $-3.98M | $-4.87M | $-2.68M | $-4.42M | $-3.00M | - |
| Avg Forecast | $-11.16M | $-11.16M | $-11.16M | $-11.86M | $-12.56M | $-12.56M | $-12.91M | $-13.08M | $-6.43M | $-10.56M | $-10.05M | $-11.72M | $-8.11M | $-9.42M | $-7.95M | $-6.91M | $-6.07M | $-3.38M | $-7.06M | - | - |
| High Forecast | $-10.04M | $-10.04M | $-10.04M | $-10.67M | $-11.29M | $-10.63M | $-11.61M | $-11.76M | $-6.43M | $-9.50M | $-9.04M | $-10.54M | $-7.29M | $-8.47M | $-7.35M | $-6.38M | $-5.61M | $-2.70M | $-6.53M | - | - |
| Low Forecast | $-12.01M | $-12.01M | $-12.01M | $-12.76M | $-13.51M | $-14.49M | $-13.88M | $-14.07M | $-6.44M | $-11.36M | $-10.81M | $-12.61M | $-8.72M | $-10.13M | $-8.46M | $-7.35M | $-6.46M | $-4.05M | $-7.51M | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 1065.39% | 1046.43% | 0.73% | 0.35% | 0.55% | 0.98% | 0.58% | 0.80% | 0.79% | 0.63% | - | - |
MaxCyte's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MXCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
MaxCyte SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $13.87B | $14.10B | $13.79M | $11.03M | $10.95M | $12.03M | $10.47M | $10.06M | $8.86M | $7.54M | $3.44M | - |
| Avg Forecast | $11.64M | $10.40M | $10.05M | $9.16M | $7.29M | $6.87M | $7.33M | $6.91M | $12.37M | $8.17M | $9.81M | $7.62M | $11.41M | $9.60M | $8.50M | $7.79M | $8.80M | $6.70M | $5.33M | $12.32M | $7.73M |
| High Forecast | $12.32M | $11.00M | $10.64M | $9.69M | $7.72M | $7.14M | $7.76M | $7.31M | $14.22M | $8.64M | $10.38M | $8.06M | $12.08M | $10.16M | $8.91M | $8.17M | $9.23M | $7.03M | $5.59M | $12.93M | $8.11M |
| Low Forecast | $10.74M | $9.59M | $9.27M | $8.45M | $6.73M | $6.60M | $6.77M | $6.37M | $10.53M | $7.53M | $9.05M | $7.03M | $10.53M | $8.86M | $8.00M | $7.33M | $8.29M | $6.31M | $5.01M | $11.60M | $7.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1698.35% | 1436.99% | 1.81% | 0.97% | 1.14% | 1.42% | 1.34% | 1.14% | 1.32% | 1.41% | 0.28% | - |
MaxCyte's average Quarter SG&A projection for Dec 23 is $12.37M, based on 4 Wall Street analysts, with a range of $10.53M to $14.22M. The forecast indicates a -99.91% fall compared to MXCT last annual SG&A of $13.87B (Sep 23).
MaxCyte EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-108.77 | $-101.99 | $-0.08 | $-0.03 | $-0.05 | $-0.08 | $-0.04 | $-0.05 | $-0.03 | $-0.05 | $-0.05 | - |
| Avg Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.11 | $-0.12 | $-0.12 | $-0.12 | $-0.13 | $-0.06 | $-0.10 | $-0.10 | $-0.11 | $-0.08 | $-0.09 | $-0.08 | $-0.07 | $-0.06 | $-0.06 | $-0.07 | - | - |
| High Forecast | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.11 | $-0.10 | $-0.11 | $-0.11 | $-0.06 | $-0.09 | $-0.09 | $-0.10 | $-0.07 | $-0.08 | $-0.07 | $-0.06 | $-0.05 | $-0.05 | $-0.06 | - | - |
| Low Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.13 | $-0.06 | $-0.11 | $-0.10 | $-0.12 | $-0.08 | $-0.10 | $-0.08 | $-0.07 | $-0.06 | $-0.06 | $-0.07 | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 1077.68% | 1062.40% | 0.75% | 0.36% | 0.56% | 1.01% | 0.59% | 0.83% | 0.52% | 0.74% | - | - |
According to undefined Wall Street analysts, MaxCyte's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MXCT previous annual EPS of $NaN (undefined).
MaxCyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RPID | Rapid Micro Biosystems | $0.84 | $8.00 | 852.38% | Hold |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| MXCT | MaxCyte | $4.03 | $8.00 | 98.51% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| IRMD | IRadimed | $48.47 | $60.00 | 23.79% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
MXCT Forecast FAQ
Is MaxCyte a good buy?
Yes, according to 2 Wall Street analysts, MaxCyte (MXCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of MXCT's total ratings.
What is MXCT's price target?
MaxCyte (MXCT) average price target is $8 with a range of $8 to $8, implying a 98.51% from its last price of $4.03. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MaxCyte stock go up soon?
According to Wall Street analysts' prediction for MXCT stock, the company can go up by 98.51% (from the last price of $4.03 to the average price target of $8), up by 98.51% based on the highest stock price target, and up by 98.51% based on the lowest stock price target.
Can MaxCyte stock reach $6?
MXCT's average twelve months analyst stock price target of $8 supports the claim that MaxCyte can reach $6 in the near future.
What are MaxCyte's analysts' financial forecasts?
MaxCyte's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $30.85M (high $32.52M, low $28.75M), average EBITDA is $-17.744M (high $-16.532M, low $-18.7M), average net income is $-51.098M (high $-45.291M, low $-55.953M), average SG&A $28.4M (high $29.93M, low $26.46M), and average EPS is $-0.488 (high $-0.433, low $-0.535). MXCT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $44.8M (high $47.42M, low $41.34M), average EBITDA is $-25.765M (high $-23.772M, low $-27.268M), average net income is $-45.344M (high $-40.786M, low $-48.784M), average SG&A $41.24M (high $43.65M, low $38.05M), and average EPS is $-0.433 (high $-0.39, low $-0.466).
Did the MXCT's actual financial results beat the analysts' financial forecasts?
Based on MaxCyte's last annual report (Dec 2023), the company's revenue was $41.29M, beating the average analysts forecast of $41.24M by 0.11%. Apple's EBITDA was $-40.329M, beating the average prediction of $-23.719M by 70.03%. The company's net income was $-37.923M, missing the average estimation of $-38.76M by -2.16%. Apple's SG&A was $57.04M, beating the average forecast of $37.97M by 50.24%. Lastly, the company's EPS was $-0.0004, missing the average prediction of $-0.37 by -99.89%. In terms of the last quarterly report (Dec 2023), MaxCyte's revenue was $15.66M, beating the average analysts' forecast of $13.44M by 16.53%. The company's EBITDA was $15.66M, missing the average prediction of $-7.731M by -302.63%. MaxCyte's net income was $0, missing the average estimation of $-6.433M by -100.00%. The company's SG&A was $0, missing the average forecast of $12.37M by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $-0.0615 by -100.00%